A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes

BACKGROUND: The antihypertensive compound hydralazine is a known demethylating agent. This phase I study evaluated the tolerability and its effects upon DNA methylation and gene reactivation in patients with untreated cervical cancer. METHODS: Hydralazine was administered to cohorts of 4 patients at...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Zambrano, Pilar, Segura-Pacheco, Blanca, Perez-Cardenas, Enrique, Cetina, Lucely, Revilla-Vazquez, Alma, Taja-Chayeb, Lucía, Chavez-Blanco, Alma, Angeles, Enrique, Cabrera, Gustavo, Sandoval, Karina, Trejo-Becerril, Catalina, Chanona-Vilchis, Jose, Duenas-González, Alfonso
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2005
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC1131894/
https://ncbi.nlm.nih.gov/pubmed/15862127
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-5-44
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados